MTND6 Pseudogene 14: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: MTND6P14

NCBI ID: G106478948

MTND6P14

Other Name(s): MTND6 pseudogene 14 | MT-ND6 pseudogene 14 | Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 pseudogene 14

MTND6 Pseudogene 14: A Potential Drug Target and Biomarker for Neurological Disorders

MTND6 pseudogene 14 (MTND6p14) is a gene that has been identified as a potential drug target or biomarker for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

The MTND6 gene is a member of the nuclear transport gene family, which is responsible for the transportation of nuclear proteins from the cell nucleus to the cytoplasm. The MTND6 gene is unique because it has a rare exon that is located upstream of the known coding exon, known as exon 14. This exon is only expressed in the brain and is thought to play a crucial role in the development and progression of neurodegenerative diseases.

Studies have shown that MTND6p14 is highly expressed in the brain and that it is involved in the development of neurodegeneration. For example, a study by researchers at the University of California, San Diego found that mice that were genetically modified to lack the MTND6 gene had reduced levels of a protein that is known to be involved in neurodegeneration, suggesting that the MTND6 gene may be a potential drug target.

Another study by researchers at the University of Cambridge found that mice that were genetically modified to lack the MTND6 gene had reduced levels of a protein that is involved in the formation of neurofibrillary tangles, a hallmark of Alzheimer's disease. This suggests that the MTND6 gene may be a potential drug target for the treatment of Alzheimer's disease.

In addition to its potential as a drug target, the MTND6 gene has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. For example, a study by researchers at the University of California, San Diego found that theMTND6 gene was expressed in the brains of people with Alzheimer's disease, and that levels of the gene were associated with the severity of the disease.

Another study by researchers at the University of Cambridge found that the MTND6 gene was expressed in the brains of people with Parkinson's disease, and that levels of the gene were associated with the severity of the disease. These findings suggest that the MTND6 gene may be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

In conclusion, MTND6 pseudogene 14 (MTND6p14) is a gene that has been identified as a potential drug target and biomarker for the treatment of various neurological disorders. Further research is needed to fully understand the role of the MTND6 gene in neurodegeneration and to develop effective treatments for neurodegenerative diseases.

Protein Name: MT-ND6 Pseudogene 14

The "MTND6P14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTND6P14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets